Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trelagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trelagliptin SCHEMBL19534887 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL29364762 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL4468875 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL28390472 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL175727 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL175726 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL29349599 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL27964065 | 0.87 | DPP4 (0.86) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL28151193 | 0.87 | DPP4 (0.86) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL18381012 | 0.86 | DPP4 (0.79) | DPP4OPRM1OPRK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466864-A | Crystal preparation method of trelagliptin succinate | 迪嘉药业集团股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-115448887-A | Trelagliptin succinate intermediate impurity and preparation method and application thereof | 河北国龙制药有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-114886864-A | Trelagliptin succinate pharmaceutical preparation and preparation method thereof | 河北戴桥医药科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114292240-A | Preparation method of trelagliptin impurity | 深圳市祥根生物医药有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-109280028-B | Quinoline compound and application thereof in DPP-4 enzyme inhibitor | 上海医药工业研究院 | 2022-03-25 | — | — | CN | disclosed |
| CN-114105949-A | Trelagliptin impurity compound and preparation method thereof | 鲁南制药集团股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114105948-A | Trelagliptin impurity compound | 鲁南制药集团股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| CN-108680678-B | Method for determining trelagliptin related substances | 江苏万川医疗健康产业集团有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11013738-B2 | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA (ES) | 2021-05-25 | — | — | US | disclosed |
| WO-2012170702-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012145603-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145604-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012135570-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012040279-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20090042863-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1970063-A1 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, SLC5A2 | DPP4 4/4885OPRM1 1034/4885OPRK1 1557/4885 |
| US-11013738-B2 | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases | DPP4, DPP3, DPP9 | DPP4 1/4885OPRM1 4359/4885OPRK1 4105/4885 |
| US-20090042863-A1 | Therapeutic Agent for Diabetes | IAPP, GPR119, SLC5A2 | DPP4 12/4885OPRM1 4441/4885OPRK1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.